The transcriptional co-activator YAP first came to light as an oncogene when genome wide studies revealed its expression was amplified in human ovarian and hepatocellular cancers, and its overexpression had transforming properties in mammary epithelial cells16, 32. This evidence concerns the gene YAP1 and hepatocellular carcinoma.